Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 15, Issue 3, 2003, Pages 317-325

  Nordahl, Thomas E ^a   Salo, Ruth ^b   Leamon, Martin ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; AMPHETAMINE; CARRIER PROTEIN; CHOLINE; COCAINE; CREATINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR; FLUORODEOXYGLUCOSE F 18; HOMOVANILLIC ACID; INOSITOL; METHAMPHETAMINE; N ACETYLASPARTIC ACID; N(G) NITROARGININE METHYL ESTER; NEUROTRANSMITTER; NITRIC OXIDE SYNTHASE INHIBITOR; RESERPINE; SEROTONIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ATTENTION; BEHAVIOR; BRAIN ELECTROPHYSIOLOGY; BRAIN METABOLISM; CHEMICAL STRUCTURE; COGNITION; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG STRUCTURE; EVENT RELATED POTENTIAL; HUMAN; MEMORY; NEUROPSYCHOLOGY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SEROTONINERGIC SYSTEM; TASK PERFORMANCE;

EID: 0042662779     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.15.3.317     Document Type: Review

References (88)

1. Anglin M, Burke C, Perrochet B, et al: History of the methamphetamine problem. J Psychoactive Drugs 2000; 32:137-41
2. Office of National Drug Control Policy: National Drug Control Strategy 2001 - ONDCP (Web Page). 16 August 2001; Available at http://www.whitehousedrugpolicy.gov/publications/policy/ndcs01/chap2.html#5. (Accessed 13 November 2001)
3. Community Epidemiology Work Group: Epidemiologic Trends in Drug Abuse Advance Report, June 2001 (Web Page). 3 August 2001; Available at http://165.112.78.61/CEWG/AdvancedRep/601ADV/601adv.html. (Accessed 13 November 2001)
4. U.S. Drug Enforcement Agency: Drug trafficking in the United States (Web Page). September 2001; Available at http:// www.dea.gov/pubs/intel/01020/index.html. (Accessed 13 November 2001
5. U.S. Drug Enforcement Agency: Drug trafficking in the United States (Web Page). September 1999; Available at http://www. dea.gov/pubs/intel/99024/99024.html. (Accessed 13 November 2001)
6. Marshall DR. Methamphetamine trafficking, use, abuse and clandestine drug laboratories. Senate Judiciary Committee testimony (Web Page). 28 July 1999. Available at http://www. dea.gov/pubs/cngrtest/ct072899.html. (Accessed 13 November 2001)
7. Gonzalez Castro F, Barrington E, Walton M, et al: Cocaine and methamphetamine: differential addiction rates. Psychol Addict Behav 2000; 14:390-396
8. Cho AK, Kumagai Y: Metabolism of amphetamine and other arylisopropylamines in Amphetamine and Its Analogs: Psychopharmacology, Toxicology, and Abuse, Cho AK, Segal DS. San Diego: Academic Press, 1994
9. Segal D, Kuczenski R. Repeated binge exposures to amphetamine and methamphetamine: behavioral and neurochemical characterization. J Pharmacol Exp Ther 1997; 282:561-573
10. Sato M, Chen C, Akiyama K, et al: Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983; 18:429-440
11. Iwanami A, Sugiyama A, Kuroki N, et al: Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan: a preliminary report. Acta Psychiatr Scand 1994; 89:428-432
12. Yui K, Goto K, Ikemoto S, et al: Monoamine neurotransmitter function and spontaneous recurrence of methamphetamine psychosis. Annals New York Academy of Sciences 1996; 81:415-429
13. American Psychiatric Association: Diagnostic and statistical manual of mental disorders: DSM-IV-TR, 4th edition, text revision. Washington, DC: American Psychiatric Association, 2000
14. Liang NY, Rutledge CO: Evidence for carrier-mediated efflux of dopamine from corpus striatum, Biochem Pharmacol 1982; 31:983-992
15. Sulzer D, Maidment NT, Rayport S: Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 1993; 60:527-535
16. Ricaurte GA, Schuster CR, Seiden LS: Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res 1984; 303: 359-364
17. Seiden LS, Ricaurte GA: Neurotoxicity of methamphetamine and related drugs, in Psychopharmacology: the third generation of Progress, Meltzer H. Edited by New York, Raven Press
18. Wagner GC, Ricaurte GA, Seiden LS, et al:. Long-lasting depletions of striatal DA and loss of DA uptake sites following repeated administration of methamphetamine. Brain Res 1980; 181:151-160
19. O'Dell SJ, Weihmuller FB, Marshall JF: Methamphetamine-induced dopamine overflow and injury to striatal dopamine terminals: attenuation by dopamine D1 or D2 antagonists. J Neurochem 1993; 60:1792-1799
20. Axt KJ, Commins DL, Vosmer G, et al: Alpha-methyl paratyrosine pretreatment partially prevents methamphetamine-induced endogenous neurotoxin formation. Brain Res 1990; 515:269-276
21. Fumagalli F, Gainetdinov RR, Valenzano KJ, et al: Role of dopamine transporter in methamphetamine-induced neurotoxicity: Evidence from mice lacking the transporter. J Neurosci 1998; 18:4861-4869
22. Marek GH, Vosmer G, Seiden LS: Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res 1990; 513:274-279
23. Schmidt CH, Gibb JW: Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: Effects of amfonelic acid. Eur J Pharmacol 1985; 109:73-80
24. Yuan J, Callahan BT, McCann UD, et al: Evidence against an essential role of Endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity. J Neurochem 2001; 77:1338-1347
25. Bowyer JF, Davies DL, Schmued L, et al: Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 1994; 268:1571-1580
26. Hotchkiss AJ, Gibb JW: Long term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther 1980; 214: 257-262
27. Ricaurte GA, Guillery RW, Seiden LS, et al: Dopamine nerve terminal degeneration produced by high doses of methamphetamine in the rat brain. Brain Res 1982; 235:93-103
28. McCann UD, Wong DF, Yokoi F, et al: Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with (C-11)-WIN-35,428. J Neurosci 1998; 18:8417-8422
29. Sekine Y, Iyo M, Ouchi Y, et al: N Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psych, 2001; 158:1206-1214
30. Volkow ND, Chang L, Wang GJ, et al: Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158:377-382
31. Ricaurte GA, Schuster CR, Seiden LS: Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study. Brain Res 1980; 193:153-163
32. Johnson M, Stone DM, Hanson GR, et al: Role of the dopaminergic nigrostriatal pathway in methamphetamine-induced depression of the neostriatal serotonergic system. Eur J Pharmacol 1987; 135:231-234
33. Sonsalla PK, Gibb JW, Hanson G.R: Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther 1986; 238:932-937
34. Stone DM, Stahl DC, Hanson GR, et al: The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol. 1986; 128:41-48
35. Schmidt CJ, Ritter JK, Sonsalla PK, et al: Role of dopamine in the neurotoxic effects of methamphetamine J Pharmcol Exp Ther 1985; 233:539-544
36. Callahan BT, Cord BJ, Ricaurte GA: Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine Synapse 2001; 40:113-121
37. PUB:Zhou FC, Bledsoe S., Methamphetamine causes rapid varicosis, perforation and definitive degeneration of serotonin fibers: An immunocytochemical study of serotonin transporters. Neuroscience NET, 1996; 1
38. McCann UD, Szabo Z, Scheffel U, et al: Positron emission tomographic evidence of toxic effect of MDMA ('Ectasy') on brain serotonin neurons in human beings. Lancet 1998b; 352:1437-1445
39. Abekawa T, Ohmori T, Koyama T: Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens. Brain Res 1994; 643:276-281
40. Nash JF, Yamamoto BK: Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res 1992; 581:237-243
41. Sonsalla PK, Nicklas WW, Heikkila R: Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 1989; 243:398-400
42. Sonsalla PK, Riordan DE, Heikkila RE: Competitive and non-competitive antagonists at N-methyl-d-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J Pharmacol Exp Ther 1991; 256:506-512
43. Weihmuller, FB O'Dell, SJ Marshall, JF: MK-801 protection against methamphetamine-induced striatal dopamine terminal injury is associated with attenuated dopamine overflow. Synapse 1992; 11:155-163
44. Abekawa T, Ohmori T, Koyama T: Effects of nitric oxide synthesis inhibition on methamphetamine-induced dopaminergic and serotonergic neurotoxicity in the rat brain. J Neural Transm 1996; 103:671-680
45. Pfefferbaum A, Adalsteinsson E, Spielman D, et al: In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. Arch Gen Psychiatry 1999; 56:185-192
46. Ernst T, Chang L, Leonido-Yee M, et al: Evidence for long-term neurotoxicity associated with methamphetamine abuse a H-MRS study. Neurology 2000; 54:1344-1349
47. Nordahl TE, Salo RE, Poissin K, et al: Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine dependent subjects: a Proton MRS study. Presented at the Annual Meeting of Soc Neuroscience, 2001
48. Taylor MJ, Alhassoon OM, Schweinsburg BC, et al: MR spectroscopy in HIV and stimulant dependence. J Int Neuropsychol Soc 2000; 6:83-85
49. Bartzokis G, Beckson M, Lu PH, et al: Age-related brain volume reductions in amphetamine and cocaine addicts and normal controls: implications for addiction research. Psychiatry Re 2000; 98:93-102
50. London E, Dong Y, Simon SL, et al: Brain metabolism during early abstinence from methamphetamine abuse. Presented at the Annual Meeting of the Am College of Neuropsychopharmacology, 2001
51. Harvey DC, Lacan G, Tanious SP, et al: Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 2000; 871:259-270
52. Wilson JM, Kalasinsky KS, Levey AI, et al: Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996; 2:699-703
53. Volkow ND, Chang L, Wang GJ, et al:Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci, 2001; 21:9414-9418
54. Bolla KI, Funderburk FR, Cadet JL:Differential effects of cocaine and cocaine alcohol on neurocognitive performance. Neurology 2000; 54:2285-2292
55. Bolla KI, Rothman R, Cadet JL:.Dose-related neurobehavioral effects of chronic cocaine use. J Neuropsychiatry Clin Neurosci 1999; 11:361-369
56. Gillen RW, Kranzler HR, Bauer LO, et al: Neuropsychologic findings in cocaine-dependent outpatients. Prog Neuro psychopharmacol Biol Psychiatry 1998; 22:1061-1076
57. Horner MD: Attentional functioning in abstinent cocaine abusers. Drug Alcohol Depend 1999; 54:19-33
58. Robinson JE, Heaton RK, O'Malley SS: Neuropsychological functioning in cocaine abusers with and without alcohol dependence. J Int Neuropsychological Soc 1999; 5:10-19
59. Rosselli M, Ardila A: Cognitive effects of cocaine and polydrug abuse. J Clin Exp Neuropsychol 1996; 18:122-135
60. Smelson DA, Roy A, Santana S, et al: Neuropsychological deficits in withdrawn cocaine-dependent males. Am J Drug Alcohol Abuse 1999; 25:377-381
61. Fleckenstein A, Gibb J, Hanson G: Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol 2000; 406:1-13
62. Kornetsky C, Mirsky AF, Kessler EK, et al: The effects of d-amphetamine on behavioral deficits produced by sleep loss in humans. J Pharmacol 1959; 127:46-50
63. Seashore RH, Ivy AC: Effects of analeptic drugs in relieving fatigue. Psychological Monographs 1953; 67:1-16
64. Soetens E, Casaer S, D'Hooge R, et al: Effect of amphetamine on long-term retention of verbal material. Psychopharmacology 1995; 119:155-162
65. Grinspoon L, Hedblom P: The Speed Culture. Harvard University Press, Cambridge, Mass 1975
66. Fleming K, Bigelow LB, Weinberger DR, et al: Neuropsychological effects of amphetamine may correlate with personality characteristics. Psychopharmacol Bull 1995; 31:357-362
67. Burns JT, House RF, Fensch FC, et al: Effects of magnesium pemoline and dextroamphetamine on human learning. Science 1967; 155:849-851
68. Rogers RD, Everitt BJ, Baldacchino A, et al: Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depeleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology 1999; 20:322-339
69. Salo R, Nordahl TE, Possin K, et al. Reduced cognitive inhibition in methamphetamine dependent individuals. (Abstract presented at Society of Neuroscience, San Diego, CA 2001)
70. Simon SL, Domier C, Carnell J, et al: Cognitive impairment in individuals currently using methamphetamine. Am J Addict 2000; 9:222-231
71. Ornstein TJ, Iddon JL, Baldaccino AM, et al: Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 2000; 23:113-126
72. Squire LR, Zola-Morgan S: Memory: brain systems and behavior. Trends Neurosci 1988; 4:170-175
73. Tulving E, Schacter DL: Priming and human memory systems. Science. American Association for the Advancement of Science 1990; 4940:301-306
74. Cohen JD, Servan-Schreiber DS: A theory of dopamine function and its role in cognitive deficits in schizophrenia. Schizophr Bull 1993; 19:85-104
75. Baunez C, Robbins TW: Effects of dopamine depletion of the dorsal striatum and further interaction with subthalamic nucleus lesions in an attentional task in the rat. Neuroscience 1999; 92:1343-1356
76. Roberts AC, De Saliva MA, Wilkinson LS, et al: 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine. J Neurosci 1994; 14: 2531-2544
77. Alexander, GE, DeLong ME, Strick PL: Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 1986; 9:357-381
78. Cools AR, van den Bercken JHL, Horstinck NW, et al: Cognitive and motor shifting aptitude disorder in Parkinson's disease. J Neurol Neurosurg Psychiatry 1984; 47:443-453
79. Harrington DL, Haaland KY: Sequencing in Parkinson's disease. Brain 1991; 114:99-115
80. Downes JJ, Roberts AC, Sahahkian BJ, et al: Impaired extradimensional shift performance in unmedicated and medicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychologia 1989; 26:1329-1343
81. Harrison AA, Everitt BJ, Robbins TW: Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms. Psychopharmacology 1997; 133:329-342
82. Coull JT, Sahakian BJ, Middleton HC, et al: Differential effects of clonidine, haloperidol, diazepam and tryptophan depletion on focussed attention and attentional search. Psychopharmacology 1995; 121:222-230
83. Soubrie P: Reconciling the role of central serotonin neurons in human and animal behavior. Behav Brain Sci 1986; 9:319-364
84. Park SB, Coull JT, McShane RH, et al: Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology 1994; 33:575-588
85. Riedel WJ, Klaases T, Deutz NEP, et al: Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology 1999; 141:362-369
86. Takeuchi S, Jodo E, Suzuki Y, et al: Effects of repeated administration of methamphetamine on P3-like potentials in rats. Int J Psychophysiol 1999; 2:183-192
87. Iwanami A, Suga I, Kato N, et al: Event-related potentials in methamphetamine psychosis during an auditory discrimination task. A preliminary report. Eur Arch Psychiatry Clin Neurosci 1993; 242:203-208
88. Iwanami A, Kuroki N, Iritani S, et al: P3a of event-related potential in chronic methamphetamine dependence. J Nerv Ment Dis 1998; 186:746-751